Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-07-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/7/e012095.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849418750138253312 |
|---|---|
| author | Egbert F Smit Willemijn S M E Theelen Michiel M Smeenk Vincent van der Noort Hanieh Abedian Kalkhoran Jeroen J M A Hendrikx |
| author_facet | Egbert F Smit Willemijn S M E Theelen Michiel M Smeenk Vincent van der Noort Hanieh Abedian Kalkhoran Jeroen J M A Hendrikx |
| author_sort | Egbert F Smit |
| collection | DOAJ |
| format | Article |
| id | doaj-art-211a0f075ada46458cdc97f392a2e921 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-211a0f075ada46458cdc97f392a2e9212025-08-20T03:32:20ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-07-0113710.1136/jitc-2025-012095Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by ZhuEgbert F Smit0Willemijn S M E Theelen1Michiel M Smeenk2Vincent van der Noort3Hanieh Abedian Kalkhoran4Jeroen J M A Hendrikx57 Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, NetherlandsDepartment of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, The NetherlandsDepartment of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, The Netherlands2 Department of Biometrics, Netherlands Cancer Institute, Amsterdam, NetherlandsDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The NetherlandsDepartment of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlandshttps://jitc.bmj.com/content/13/7/e012095.full |
| spellingShingle | Egbert F Smit Willemijn S M E Theelen Michiel M Smeenk Vincent van der Noort Hanieh Abedian Kalkhoran Jeroen J M A Hendrikx Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu Journal for ImmunoTherapy of Cancer |
| title | Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu |
| title_full | Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu |
| title_fullStr | Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu |
| title_full_unstemmed | Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu |
| title_short | Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu |
| title_sort | response to comment on pembrolizumab hybrid dosing is non inferior to flat dosing in advanced non small cell lung cancer a real world retrospective bicenter cohort study by zhu |
| url | https://jitc.bmj.com/content/13/7/e012095.full |
| work_keys_str_mv | AT egbertfsmit responsetocommentonpembrolizumabhybriddosingisnoninferiortoflatdosinginadvancednonsmallcelllungcancerarealworldretrospectivebicentercohortstudybyzhu AT willemijnsmetheelen responsetocommentonpembrolizumabhybriddosingisnoninferiortoflatdosinginadvancednonsmallcelllungcancerarealworldretrospectivebicentercohortstudybyzhu AT michielmsmeenk responsetocommentonpembrolizumabhybriddosingisnoninferiortoflatdosinginadvancednonsmallcelllungcancerarealworldretrospectivebicentercohortstudybyzhu AT vincentvandernoort responsetocommentonpembrolizumabhybriddosingisnoninferiortoflatdosinginadvancednonsmallcelllungcancerarealworldretrospectivebicentercohortstudybyzhu AT haniehabediankalkhoran responsetocommentonpembrolizumabhybriddosingisnoninferiortoflatdosinginadvancednonsmallcelllungcancerarealworldretrospectivebicentercohortstudybyzhu AT jeroenjmahendrikx responsetocommentonpembrolizumabhybriddosingisnoninferiortoflatdosinginadvancednonsmallcelllungcancerarealworldretrospectivebicentercohortstudybyzhu |